Director Carl Dambkowski Files Intent to Sell $6.37 Million in Oruka Therapeutics Stock
ORKA has more than doubled off its 52-week low of $10.255.
Summary
Director Carl Dambkowski plans to sell $6.37 million worth of Oruka Therapeutics stock, a significant insider disposition following recent positive company news.
Key Events · Ownership and Investor Activity · ORKA
-
Director Files Intent to Sell Shares
Carl Dambkowski, a Director, filed a Form 144 indicating an intent to sell 105,000 shares of common stock.
-
Significant Value of Proposed Sale
The shares to be sold are valued at approximately $6.37 million, representing about 0.18% of the company's market capitalization.
-
Shares Acquired via Options and Distribution
The shares include 62,260 acquired through the exercise of stock options and 42,740 from a partnership distribution.
-
Follows Recent Capital Raise and Positive Data
This intent to sell follows a recent $700 million public offering and strong Phase 2a clinical trial results for ORKA-001.
Analysis · ORKA · Life Sciences
Director Carl Dambkowski has filed a Form 144 indicating an intent to sell 105,000 shares of Oruka Therapeutics common stock, valued at approximately $6.37 million. This proposed sale, which includes shares acquired through option exercise and partnership distribution, represents a notable disposition by an insider following recent positive clinical trial data and a large public offering. While not an immediate sale, it signals a director's intent to reduce their holdings.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ORKA was trading at $58.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $10.26 to $91.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.